BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 35488033)

  • 41. Patient-derived xenografts undergo mouse-specific tumor evolution.
    Ben-David U; Ha G; Tseng YY; Greenwald NF; Oh C; Shih J; McFarland JM; Wong B; Boehm JS; Beroukhim R; Golub TR
    Nat Genet; 2017 Nov; 49(11):1567-1575. PubMed ID: 28991255
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Somatostatin Receptors and Chemokine Receptor CXCR4 in Lymphomas: A Histopathological Review of Six Lymphoma Subtypes.
    Juntikka T; Vaittinen S; Vahlberg T; Jyrkkiö S; Minn H
    Front Oncol; 2021; 11():710900. PubMed ID: 34307181
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Human B Lymphomas Reveal Their Secrets Through Genetic Mouse Models.
    Mossadegh-Keller N; Brisou G; Beyou A; Nadel B; Roulland S
    Front Immunol; 2021; 12():683597. PubMed ID: 34335584
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinicopathological features of aggressive B-cell lymphomas including B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell and Burkitt lymphomas: a study of 44 patients from Argentina.
    Bürgesser MV; Gualco G; Diller A; Natkunam Y; Bacchi CE
    Ann Diagn Pathol; 2013 Jun; 17(3):250-5. PubMed ID: 23246412
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PDX models recapitulate the genetic and epigenetic landscape of pediatric T-cell leukemia.
    Richter-Pechańska P; Kunz JB; Bornhauser B; von Knebel Doeberitz C; Rausch T; Erarslan-Uysal B; Assenov Y; Frismantas V; Marovca B; Waszak SM; Zimmermann M; Seemann J; Happich M; Stanulla M; Schrappe M; Cario G; Escherich G; Bakharevich K; Kirschner-Schwabe R; Eckert C; Muckenthaler MU; Korbel JO; Bourquin JP; Kulozik AE
    EMBO Mol Med; 2018 Dec; 10(12):. PubMed ID: 30389682
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Early development of human lymphomas in a prostate cancer xenograft program using triple knock-out immunocompromised mice.
    Wetterauer C; Vlajnic T; Schüler J; Gsponer JR; Thalmann GN; Cecchini M; Schneider J; Zellweger T; Pueschel H; Bachmann A; Ruiz C; Dirnhofer S; Bubendorf L; Rentsch CA
    Prostate; 2015 May; 75(6):585-92. PubMed ID: 25585936
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
    Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
    BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Distribution and ZAP-70 expression of WHO lymphoma categories in Shanxi, China: a review of 447 cases using a tissue microarray technique.
    Wang J; Young L; Win W; Taylor CR
    Appl Immunohistochem Mol Morphol; 2005 Dec; 13(4):323-32. PubMed ID: 16280661
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Significance of mTOR (mammalian target of rapamycin) activity in human lymphomas].
    Márk Á
    Magy Onkol; 2014 Jun; 58(2):143-8. PubMed ID: 25010764
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting Lymphoma-associated Macrophage Expansion via CSF1R/JAK Inhibition is a Therapeutic Vulnerability in Peripheral T-cell Lymphomas.
    Gao X; Kady N; Wang C; Abdelrahman S; Gann P; Sverdlov M; Wolfe A; Brown N; Reneau J; Robida AM; Murga-Zamalloa C; Wilcox RA
    Cancer Res Commun; 2022 Dec; 2(12):1727-1737. PubMed ID: 36970721
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Among diffuse large B-cell lymphomas, T-cell-rich/histiocyte-rich BCL and CD30+ anaplastic B-cell subtypes exhibit distinct clinical features.
    Maes B; Anastasopoulou A; Kluin-Nelemans JC; Teodorovic I; Achten R; Carbone A; De Wolf-Peeters C;
    Ann Oncol; 2001 Jun; 12(6):853-8. PubMed ID: 11484964
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.
    Salles G; Gopal AK; Minnema MC; Wakamiya K; Feng H; Schecter JM; Wang M
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):275-284. PubMed ID: 30795996
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Bone marrow immunophenotypes of 112 cases of lymphoid system malignant diseases].
    Ling JY; Sun XF; Yan SL; He LR; Zhen ZJ; Xia Y
    Ai Zheng; 2007 Apr; 26(4):418-22. PubMed ID: 17430665
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype: an integrative clinical, pathological and molecular case series study.
    Wang L; Rocas D; Dalle S; Sako N; Pelletier L; Martin N; Dupuy A; Tazi N; Balme B; Vergier B; Beylot-Barry M; Carlotti A; Bagot M; Battistella M; Chaby G; Ingen-Housz-Oro S; Gaulard P; Ortonne N
    Br J Dermatol; 2022 Dec; 187(6):970-980. PubMed ID: 35895386
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas.
    Krenacs L; Himmelmann AW; Quintanilla-Martinez L; Fest T; Riva A; Wellmann A; Bagdi E; Kehrl JH; Jaffe ES; Raffeld M
    Blood; 1998 Aug; 92(4):1308-16. PubMed ID: 9694719
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative ultrastructural study of cytotoxic granules in nasal natural killer cell lymphoma, intestinal T-cell lymphoma, and anaplastic large cell lymphoma.
    Sadahira Y; Akisada K; Sugihara T; Hata S; Uehira K; Muraki N; Manabe T
    Virchows Arch; 2001 Mar; 438(3):280-8. PubMed ID: 11315625
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Molecularly annotation of mouse avatar models derived from patients with colorectal cancer liver metastasis.
    Wang J; Xing B; Liu W; Li J; Wang X; Li J; Yang J; Ji C; Li Z; Dong B; Gao J; Shen L
    Theranostics; 2019; 9(12):3485-3500. PubMed ID: 31281492
    [No Abstract]   [Full Text] [Related]  

  • 58. Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.
    Navone NM; van Weerden WM; Vessella RL; Williams ED; Wang Y; Isaacs JT; Nguyen HM; Culig Z; van der Pluijm G; Rentsch CA; Marques RB; de Ridder CMA; Bubendorf L; Thalmann GN; Brennen WN; Santer FR; Moser PL; Shepherd P; Efstathiou E; Xue H; Lin D; Buijs J; Bosse T; Collins A; Maitland N; Buzza M; Kouspou M; Achtman A; Taylor RA; Risbridger G; Corey E
    Prostate; 2018 Dec; 78(16):1262-1282. PubMed ID: 30073676
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Establishment and evaluation of retroperitoneal liposarcoma patient-derived xenograft models: an ideal model for preclinical study.
    Xu C; Yan L; An Q; Zhang S; Guan X; Wang Z; Lv A; Liu D; Liu F; Dong B; Zhao M; Tian X; Hao C
    Int J Med Sci; 2022; 19(8):1241-1253. PubMed ID: 35928724
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Histopathologic and immunophenotypic characterization of patient-derived pediatric malignant hepatocellular tumor xenografts (PDXs).
    Patel KR; Espinoza AF; Urbicain M; Patel RH; Major A; Sarabia SF; Lopez-Terrada D; Vasudevan SA; Woodfield SE
    Pathol Res Pract; 2024 Mar; 255():155163. PubMed ID: 38394806
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.